Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis is associated with lipid abnormalities at the onset of skin disease Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Efficacy of simvastatin in plaque psoriasis: A pilot study

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce Strober, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Global burden of urticaria: Insights from the 2016 Global Burden of Disease Study Elena Maxim, BS, Chante Aksut, MD, Derrick Tsoi, BS, Robert Dellavalle,

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis Tsung-Yu Tsai, MD, Yu-Chen Huang, MD Journal.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Treatment of psoriasis vulgaris using low-dose naltrexone

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Hugh Gloster, MD, Chesahna Kindred, MBA

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study Hyun Jeong Ju, MD, Ki-Jo Kim, MD, PhD,

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.

Derek Y. Hsu, BA, Kenneth Gordon, MD, Jonathan I

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3) Andrew Blauvelt, MD, MBA, Kim A. Papp, MD, PhD, Mark G. Lebwohl, MD, Lawrence J. Green, MD, Sylvia Hsu, MD, Varsha Bhatt, PhD, Shipra Rastogi, PhD, MBA, Radhakrishnan Pillai, PhD, Robert Israel, MD Journal of the American Academy of Dermatology Volume 77, Issue 2, Pages 372-374 (August 2017) DOI: 10.1016/j.jaad.2017.03.026 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 75 (nonresponder imputation) in induction phase (baseline to week 12, pooled data) (A). Time for 25% of patients to achieve PASI 75 was estimated from bootstrap samples with the use of linear interpolation between time points. Percentage of patients achieving Physician's Global Assessment (sPGA) success (0 or 1) (nonresponder imputation) in induction phase (baseline to week 12, pooled data) (B). Time for 25% of patients to achieve sPGA was estimated from bootstrap samples with the use of linear interpolation between time points. Journal of the American Academy of Dermatology 2017 77, 372-374DOI: (10.1016/j.jaad.2017.03.026) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Change from baseline Psoriasis Area and Severity Index (PASI) in induction phase (baseline to week 12, pooled data). A repeated-measures, mixed-effects model was used to analyze the percentage change from baseline in the PASI. Symbols without black outlining indicate least-squares means; I-bars, 95% confidence intervals (CIs). Median time to 75%, 50%, and 25% reduction in mean PASI was estimated from bootstrap samples with the use of linear interpolation between time points. Multiple imputation was used to impute missing data with 3 imputed datasets. Journal of the American Academy of Dermatology 2017 77, 372-374DOI: (10.1016/j.jaad.2017.03.026) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions